Jessica A Walsh1, Oluwakayode Adejoro2, Benjamin Chastek2, Yujin Park3. 1. University of Utah & Salt Lake City Veterans Affairs Medical Center, Division of Rheumatology, Salt Lake City, UT 84132, USA. 2. Optum, Eden Prairie, MN 55344, USA. 3. Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936, USA.
Abstract
AIM: Examine treatment patterns among patients with active ankylosing spondylitis (AS) treated with a TNF inhibitor (TNFi). PATIENTS & METHODS: Patients with AS who initiated a TNFi between 1 January 2013, and 31 January 2015, were identified in the Optum Research Database. Outcomes included adherence, persistence, discontinuation and therapy modifications of the index TNFi during 12-month follow-up. RESULTS: Of the 426 patients included, 40.6% persisted on the index TNFi for ≥12 months, 31.0% discontinued, 21.4% switched to a different TNFi, and 7.0% discontinued and then restarted. Of the 333 patients who persisted on their TNFi for >90 days, 44.7% received ≥1 add-on medication. CONCLUSION: A high proportion of patients with AS switched, discontinued or modified their TNFi therapy.
AIM: Examine treatment patterns among patients with active ankylosing spondylitis (AS) treated with a TNF inhibitor (TNFi). PATIENTS & METHODS:Patients with AS who initiated a TNFi between 1 January 2013, and 31 January 2015, were identified in the Optum Research Database. Outcomes included adherence, persistence, discontinuation and therapy modifications of the index TNFi during 12-month follow-up. RESULTS: Of the 426 patients included, 40.6% persisted on the index TNFi for ≥12 months, 31.0% discontinued, 21.4% switched to a different TNFi, and 7.0% discontinued and then restarted. Of the 333 patients who persisted on their TNFi for >90 days, 44.7% received ≥1 add-on medication. CONCLUSION: A high proportion of patients with AS switched, discontinued or modified their TNFi therapy.
Authors: Jessica A Walsh; Shaobo Pei; Gopi K Penmetsa; Jianwei Leng; Grant W Cannon; Daniel O Clegg; Brian C Sauer Journal: BMC Musculoskelet Disord Date: 2018-09-05 Impact factor: 2.362